Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT04155541
Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)
Sponsor: Pfizer
View on ClinicalTrials.gov
Summary
Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical practice
Official title: Special Investigation for Vizimpro Tablets
Key Details
Gender
All
Age Range
0 Years - Any
Study Type
OBSERVATIONAL
Enrollment
40
Start Date
2020-01-24
Completion Date
2025-04-25
Last Updated
2026-06-11
Healthy Volunteers
No
Interventions
DRUG
dacomitinib hydrate
The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose should be reduced appropriately according to the patient's condition.
Locations (1)
Pfizer Japan
Tokyo, Japan